AI assistant
Sending…
Salarius Pharmaceuticals, Inc. — Director's Dealing 2018
Jan 19, 2018
35494_dirs_2018-01-19_6fbada93-1329-478d-ba4f-1187934a0836.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2018-01-17
Reporting Person: Woo Elizabeth (SVP, Investor Relations)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-17 | Stock Option (right to buy) | $3.98 | A | 50000 | Acquired | 2028-01-17 | Common Stock (50000.0) | Direct |
Footnotes
F1: The stock option will vest in 48 successive equal monthly installments measured from January 17, 2018.
More from Salarius Pharmaceuticals, Inc.
Proxy Solicitation & Information Statement
2026
Jun 4
Proxy Solicitation & Information Statement
2026
Jun 4
Regulatory Filings
2026
May 19
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Declaration of Voting Results & Voting Rights Announcements
2026
Feb 25
Major Shareholding Notification
2026
Feb 17
Proxy Solicitation & Information Statement
2026
Jan 9
Regulatory Filings
2026
Jan 8